\n<\/p>\n
HUTCHMED said on Tuesday \u200bthat Anglo-Swedish drugmaker AstraZeneca had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO \u200bcombination to treat patients with advanced \u200blung cancer.<\/strong><\/p>\n ORPATHYS is being jointly \u2060developed by AstraZeneca and \u200bHUTCHMED and is commercialised by \u200bAstraZeneca.<\/p>\n Here are some details:<\/p>\n The company said the combination extended progression-free survival \u200band improved overall survival \u200bcompared with chemotherapy. EGFR refers to epidermal growth factor receptor, a protein found on \u200bthe surface \u200bof \u2060cells that helps them grow and divide.<\/p>\n ORPATHYS \u200bhas already been approved \u200bin \u2060China based on data from a separate Phase III \u2060study, \u200bHUTCHMED said.<\/p>\n Read more:<\/p>\n Lung cancer is the leading cause of cancer death globally, accounting for almost one in four (23%) cancer deaths.1 Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.<\/p>\n Approximately 75% of NSCLC patients are diagnosed with advanced disease.<\/p>\n Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.\u200b<\/p>\n MET is a tyrosine kinase receptor that has an essential role in normal cell development.7 MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.<\/p>\n An estimated 34% of tumors will develop high levels of MET overexpression or amplification after progression on a third-generation EGFR TKI.<\/p>\n<\/div>\n
The treatment targets patients whose cancer \u200cprogressed following \u2060prior EGFR-targeted treatment.<\/p>\nmfinzi, Imdelltra combo helps lung cancer patients live longer<\/a><\/h4>\n